CN105232746A - Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating thoracic wall contusion and rib fracture and preparation method of traditional Chinese medicine preparation - Google Patents
Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating thoracic wall contusion and rib fracture and preparation method of traditional Chinese medicine preparation Download PDFInfo
- Publication number
- CN105232746A CN105232746A CN201510638080.8A CN201510638080A CN105232746A CN 105232746 A CN105232746 A CN 105232746A CN 201510638080 A CN201510638080 A CN 201510638080A CN 105232746 A CN105232746 A CN 105232746A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- preparation
- chest wall
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 94
- 208000034656 Contusions Diseases 0.000 title claims abstract description 66
- 208000027790 Rib fracture Diseases 0.000 title claims abstract description 63
- 210000000779 thoracic wall Anatomy 0.000 title claims abstract description 61
- 230000009519 contusion Effects 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 47
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 22
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 22
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 18
- 241000218176 Corydalis Species 0.000 claims abstract description 14
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 12
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 2
- 239000000843 powder Substances 0.000 claims description 26
- 240000000031 Achyranthes bidentata Species 0.000 claims description 19
- 241000202726 Bupleurum Species 0.000 claims description 19
- 239000006187 pill Substances 0.000 claims description 19
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 18
- 244000144730 Amygdalus persica Species 0.000 claims description 16
- 239000002775 capsule Substances 0.000 claims description 16
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 15
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 15
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 15
- 229940010454 licorice Drugs 0.000 claims description 15
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 12
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 244000183685 Citrus aurantium Species 0.000 claims description 11
- 235000007716 Citrus aurantium Nutrition 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 244000061520 Angelica archangelica Species 0.000 claims description 10
- 235000000228 Citrus myrtifolia Nutrition 0.000 claims description 10
- 235000016646 Citrus taiwanica Nutrition 0.000 claims description 10
- 235000012907 honey Nutrition 0.000 claims description 8
- 241000703121 Campanula rotundifolia Species 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 6
- 239000003205 fragrance Substances 0.000 claims description 6
- 240000002045 Guettarda speciosa Species 0.000 claims description 5
- 241000202807 Glycyrrhiza Species 0.000 claims description 4
- 241000208671 Campanulaceae Species 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 235000014347 soups Nutrition 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 64
- 210000004369 blood Anatomy 0.000 abstract description 64
- 230000001737 promoting effect Effects 0.000 abstract description 36
- 230000017531 blood circulation Effects 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 21
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 15
- 208000024891 symptom Diseases 0.000 abstract description 12
- 244000274050 Platycodon grandiflorum Species 0.000 abstract description 11
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 7
- 208000026435 phlegm Diseases 0.000 abstract description 7
- 230000004087 circulation Effects 0.000 abstract description 5
- 235000006751 Platycodon Nutrition 0.000 abstract description 2
- 241000405414 Rehmannia Species 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 229930189914 platycodon Natural products 0.000 abstract description 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 abstract 1
- 241000427159 Achyranthes Species 0.000 abstract 1
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 abstract 1
- 244000236521 Bupleurum rotundifolium Species 0.000 abstract 1
- 241000212322 Levisticum officinale Species 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000000994 depressogenic effect Effects 0.000 abstract 1
- 230000003028 elevating effect Effects 0.000 abstract 1
- 230000008451 emotion Effects 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 239000001645 levisticum officinale Substances 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 244000132619 red sage Species 0.000 abstract 1
- 210000000582 semen Anatomy 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 40
- 230000036407 pain Effects 0.000 description 39
- 210000004185 liver Anatomy 0.000 description 28
- 230000006870 function Effects 0.000 description 19
- 210000004072 lung Anatomy 0.000 description 18
- 230000000144 pharmacologic effect Effects 0.000 description 12
- 206010042674 Swelling Diseases 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 230000008961 swelling Effects 0.000 description 11
- 206010011224 Cough Diseases 0.000 description 10
- 241000736199 Paeonia Species 0.000 description 10
- 210000000038 chest Anatomy 0.000 description 10
- 235000006753 Platycodon grandiflorum Nutrition 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 208000014674 injury Diseases 0.000 description 9
- 208000004998 Abdominal Pain Diseases 0.000 description 8
- 206010007247 Carbuncle Diseases 0.000 description 8
- -1 acetyl saikosaponin Chemical compound 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 201000000736 Amenorrhea Diseases 0.000 description 7
- 206010001928 Amenorrhoea Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 231100000540 amenorrhea Toxicity 0.000 description 7
- 210000000748 cardiovascular system Anatomy 0.000 description 7
- 208000005171 Dysmenorrhea Diseases 0.000 description 6
- 206010013935 Dysmenorrhoea Diseases 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000037093 Menstruation Disturbances Diseases 0.000 description 4
- 206010027339 Menstruation irregular Diseases 0.000 description 4
- 206010068319 Oropharyngeal pain Diseases 0.000 description 4
- 201000007100 Pharyngitis Diseases 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 241000207199 Citrus Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- 241000180649 Panax notoginseng Species 0.000 description 3
- 235000003143 Panax notoginseng Nutrition 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 241001072909 Salvia Species 0.000 description 3
- 235000017276 Salvia Nutrition 0.000 description 3
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 239000008575 shengdi Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 2
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 2
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- 241000208173 Apiaceae Species 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 2
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 241000244365 Ligusticum sinense Species 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 208000012287 Prolapse Diseases 0.000 description 2
- 240000005809 Prunus persica Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 229930183118 Tanshinone Natural products 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 208000027744 congestion Diseases 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 208000024765 knee pain Diseases 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- OPMNROCQHKJDAQ-FKSUSPILSA-N loline Chemical compound C1C[C@@H]2O[C@H]3[C@H](NC)[C@@H]2N1C3 OPMNROCQHKJDAQ-FKSUSPILSA-N 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- BFBPISPWJZMWJN-UHFFFAOYSA-N methyl 2-[(7-hydroxy-3,7-dimethyloctylidene)amino]benzoate Chemical compound COC(=O)C1=CC=CC=C1N=CCC(C)CCCC(C)(C)O BFBPISPWJZMWJN-UHFFFAOYSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 2
- 229930192014 saikosaponin Natural products 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 235000015500 sitosterol Nutrition 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 150000008130 triterpenoid saponins Chemical class 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 229930190951 Achyranthes saponin Natural products 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000748223 Alisma Species 0.000 description 1
- 241000219317 Amaranthaceae Species 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 241000169680 Aphloia theiformis Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 235000003717 Boswellia sacra Nutrition 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 206010061386 Chest injury Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241001532196 Cordyline Species 0.000 description 1
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 1
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 206010017886 Gastroduodenal ulcer Diseases 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241001527087 Panax vietnamensis Species 0.000 description 1
- 235000017726 Panax vietnamensis Nutrition 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- GTRPODKMSBFDOI-UHFFFAOYSA-N Protopine Natural products CN1Cc2c3OCOc3ccc2C4C1Cc5cc6OCOc6cc5C4=O GTRPODKMSBFDOI-UHFFFAOYSA-N 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- ZAALQOFZFANFTF-UHFFFAOYSA-N Pseudoprotipine Natural products C1=C2C(=O)CC3=CC=4OCOC=4C=C3CN(C)CCC2=CC2=C1OCO2 ZAALQOFZFANFTF-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 description 1
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 1
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000026137 Soft tissue injury Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000005250 Spontaneous Fractures Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000021945 Tendon injury Diseases 0.000 description 1
- 208000029224 Thoracic injury Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003509 anti-fertility effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- CHWPMFMUQATVNK-ARYYTZDLSA-N dihydrosporogen AO-1 Natural products O[C@H]1[C@]2(C(C)=C)O[C@@H]2[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1 CHWPMFMUQATVNK-ARYYTZDLSA-N 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- OPMNROCQHKJDAQ-UHFFFAOYSA-N festucine Natural products C1CC2OC3C(NC)C2N1C3 OPMNROCQHKJDAQ-UHFFFAOYSA-N 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000009519 fu-yuan Substances 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- IFYYFLINQYPWGJ-UHFFFAOYSA-N gamma-decalactone Chemical compound CCCCCCC1CCC(=O)O1 IFYYFLINQYPWGJ-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- 229930195208 isotanshinone Natural products 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002630 limonoids Chemical class 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000005980 lung dysfunction Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- DLIKSSGEMUFQOK-SFTVRKLSSA-N naringenin 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C(C(=O)C[C@H](O2)C=3C=CC(O)=CC=3)C2=C1 DLIKSSGEMUFQOK-SFTVRKLSSA-N 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- RXVLWCCRHSJBJV-UHFFFAOYSA-N prunin Natural products OCC1OC(O)C(Oc2cc(O)c3C(=O)CC(Oc3c2)c4ccc(O)cc4)C(O)C1O RXVLWCCRHSJBJV-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 description 1
- 229930183842 salvianolic acid Natural products 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
技术领域technical field
本发明属于中药组合物技术领域,具体涉及一种用于治疗胸壁挫伤、肋骨骨折的中药组合物、中药制剂及其制备方法。The invention belongs to the technical field of traditional Chinese medicine compositions, and in particular relates to a traditional Chinese medicine composition for treating chest wall contusion and rib fracture, a traditional Chinese medicine preparation and a preparation method thereof.
背景技术Background technique
胸壁挫伤、肋骨骨折属于中医骨外科常见急症。胸壁挫伤多因胸胁部遭受暴力,致使软组织损伤,气血运行不畅,气滞作痛。中医医学认为胸为肺之分野,肝经之脉由下而上至胁肋,胆经之脉由上而下循胸肋,肺主气、肝藏血,气血同行于胸中,气贯胸腔,气机逆乱,肺失宣肃,气滞失畅,血瘀难得循行,诸阳受气于胸中,由于气滞血瘀,胸阳不振致津液输布受碍,水湿停聚不化而成痰。Chest wall contusion and rib fracture are common emergencies in TCM orthopedic surgery. Chest wall contusion is often caused by violence on the chest and hypochondrium, resulting in soft tissue damage, poor circulation of Qi and blood, and pain due to stagnation of Qi. Traditional Chinese medicine believes that the chest is the division of the lungs. The pulse of the liver meridian runs from bottom to top to the ribs, and the pulse of the gallbladder meridian runs from top to bottom through the chest ribs. The lungs govern qi and the liver stores blood. Qi and blood travel together in the chest, and the qi runs through the chest cavity , the movement of qi is reversed, the lungs lose their vibrancy, the stagnation of qi is unsmooth, and blood stasis is difficult to circulate. All yang receive qi in the chest. into phlegm.
肋骨骨折在胸部创伤中最为常见,多见于跌仆、撞击、交通事故等暴力直接作用于肋骨引起,尤其老年人骨质疏松容易发生、已有恶性肿瘤骨转移者易发生病理性骨折。中医学认为肋骨易被损伤,伤后出现胸壁肿痛,是由骨折筋伤,经脉破损,血溢脉外,瘀积肋下,阻滞气机所致。“气伤则痛”,“形伤则肿”。胸肋内为肺脏,胸肋受伤严重则必然影响肺脏的呼吸功能。此多因气血瘀阻,使气道不畅,肺失清肃,气上逆、气不顺所致。若瘀积胁下,也会致肝失条达,反侮肺金,发为喘咳。如胸部损伤后,积瘀生热,加上伤后损伤肺气,风、痰、瘀三者壅滞化火,也会发为咳呛不止。伤后,六淫外邪乘虚而人而致肺脏功能失调,出现喘咳及呼吸困难。Rib fractures are the most common in chest trauma, and they are mostly caused by falls, impacts, traffic accidents and other violence directly acting on the ribs, especially in the elderly who are prone to osteoporosis and those with bone metastasis of malignant tumors are prone to pathological fractures. Traditional Chinese medicine believes that ribs are easily injured, and chest wall swelling and pain after injury are caused by fractures and tendon injuries, damaged meridians, blood overflowing outside the veins, stasis under the ribs, and blockage of Qi. "Qi hurts pain", "shape hurts swelling". Inside the sternal ribs are the lungs, and severe injuries to the sternal ribs will inevitably affect the respiratory function of the lungs. This is mostly due to stagnation of qi and blood, which makes the airway unsmooth, the lungs are not cleared, and the qi is reversed and the qi is not smooth. If the blood stasis accumulates in the lower body, it will also cause the liver to lose its balance, which will injure the lung metal, resulting in wheezing and coughing. For example, after chest injury, blood stasis builds up heat, and lung qi is damaged after injury, and wind, phlegm, and blood stasis stagnate and turn into fire, which will also lead to continuous coughing and choking. After the injury, the six exogenous evils take advantage of the deficiency and cause lung dysfunction, wheezing, coughing and dyspnea.
目前,胸壁挫伤、肋骨骨折的治疗原则以有效控制疼痛、肺部物理治疗和早期活动为主。中医外科在骨折复位、固定等治疗的同时,早期(受伤10d内),伤处胸肋肿痛,局部瘀斑,拒按,深呼吸及咳嗽、喷嚏时加重,重者不敢大声说话,呼吸困难。舌黯红,或有瘀斑,苔薄白,脉弦或数。治宜活血化瘀,理气止痛。有用复元活血汤加减,使瘀去新生,气行络通,则胁痛自止。中期(受伤10d后)处疼痛缓解,但深呼吸及咳嗽时仍较痛,拒按,舌黯红,苔薄白,脉弦。治宜活血行气,疏肝止痛。方用柴胡疏肝散加减。后期(伤后6~8周)一般骨折已愈合,但可以仍遗留肋部隐隐作痛,胸部憋闷不畅,咳嗽咯痰时仍有抽痛,舌淡红,苔薄白,脉细。补肝益肾,补养气血,辅以行气活血。续骨活血汤加减。多以活血化瘀、辅以营养为主,但治疗效果有限。中药用于治疗胸壁挫伤、肋骨骨折的配方较少,中药大多以芍药、川芎、菊花等除风药为主要配方。At present, the principles of treatment for chest wall contusion and rib fracture are based on effective pain control, pulmonary physical therapy and early mobilization. In the early stage (within 10 days of injury), thoracic rib swelling and pain at the injured site, local ecchymosis, refusal to press, aggravated by deep breathing, coughing and sneezing, severe cases dare not speak loudly, and dyspnea . Dark red tongue, or ecchymosis, thin white fur, stringy or rapid pulse. It is suitable for promoting blood circulation and removing blood stasis, regulating qi and relieving pain. It is useful to add or subtract Fuyuan Huoxue Decoction to remove the blood stasis and regenerate the blood, and the circulation of qi to unblock the collaterals, so that the hypochondriac pain will stop itself. In the mid-term (after 10 days of injury), the pain was relieved, but it was still more painful when taking a deep breath and coughing, with refusal to press, dark red tongue, thin white fur, and stringy pulse. It is suitable for promoting blood circulation and promoting qi, soothing the liver and relieving pain. Recipe with Bupleurum Shugan powder addition and subtraction. In the later stage (6-8 weeks after injury), the fractures are generally healed, but there may still be dull pain in the ribs, chest tightness, and throbbing pain when coughing and expectoration, pale red tongue, thin white fur, and thready pulse. Nourish the liver and kidney, nourish qi and blood, supplemented by promoting qi and blood. Addition and subtraction of Xugu Huoxue Decoction. Most of them are based on promoting blood circulation and removing blood stasis, supplemented by nutrition, but the therapeutic effect is limited. There are few formulas of traditional Chinese medicine for treating chest wall contusion and rib fracture, and most traditional Chinese medicines use peony, Chuanxiong, chrysanthemum and other wind-removing medicines as the main formula.
现有技术中,CN1623588A的“一种治疗骨折及软组织损伤的中药组合物”公开了包括以下组分的中药组合物:苏木7-30、红花3-12、桃仁3-12、当归4-18、川芎3-12、赤芍5-20、生地5-20、乳香6-25、没药6-25、杜仲6-25、三棱5-20、莪术5-20、桂枝4-18、牛膝4-18、泽泻5-20、丹皮3-12,该中药组合物具有舒筋活血、和营通络、散瘀祛痛之功效。但是用于治疗胸壁挫伤、肋骨骨折效果欠佳。In the prior art, CN1623588A "A Traditional Chinese Medicine Composition for Treating Fractures and Soft Tissue Injuries" discloses a Chinese medicine composition comprising the following components: Hematoxylin 7-30, Safflower 3-12, Peach Kernel 3-12, Angelica 4 -18, Chuanxiong 3-12, Chishao 5-20, Rehmannia 5-20, Frankincense 6-25, Myrrh 6-25, Eucommia 6-25, Sanleng 5-20, Curcuma 5-20, Guizhi 4- 18. Achyranthes bidentata 4-18, Alisma 5-20, paeonol 3-12. The traditional Chinese medicine composition has the effects of relaxing tendons and activating blood circulation, harmonizing and dredging collaterals, dissipating blood stasis and dispelling pain. However, it is not effective for the treatment of chest wall contusion and rib fracture.
发明内容Contents of the invention
本发明的第一个目的是提供一种用于治疗胸壁挫伤、肋骨骨折的中药组合物,该中药组合物,成本较低,治疗胸壁挫伤、肋骨骨折肿痛症状疗效确切。The first object of the present invention is to provide a traditional Chinese medicine composition for treating chest wall contusion and rib fracture. The Chinese medicine composition has low cost and definite curative effect for treating chest wall contusion and rib fracture swelling and pain.
本发明的第二个目的是提供一种用于治疗胸壁挫伤、肋骨骨折的中药制剂。The second object of the present invention is to provide a Chinese medicine preparation for treating chest wall contusion and rib fracture.
本发明的第三个目的是提供一种上述的用于治疗胸壁挫伤、肋骨骨折的中药制剂的制备方法。The third object of the present invention is to provide a preparation method of the above-mentioned traditional Chinese medicine preparation for treating chest wall contusion and rib fracture.
为实现以上目的,本发明采用的技术方案为:For realizing above object, the technical scheme that the present invention adopts is:
一种用于治疗胸壁挫伤、肋骨骨折的中药组合物,由以下重量份数的组分组成:柴胡3~15份、桃仁6~12份、红花3~9份、当归尾6~15份、川芎3~12份、赤芍6~12份、牛膝6~15份、丹参3~15份、枳壳6~9份、桔梗3~10份、延胡索6~15份、木香2~12份、甘草3~6份、生地6~15份。A traditional Chinese medicine composition for treating chest wall contusion and rib fracture, which consists of the following components in parts by weight: 3-15 parts of Bupleurum bupleurum, 6-12 parts of peach kernel, 3-9 parts of safflower, 6-15 parts of angelica tail 3-12 parts of Chuanxiong, 6-12 parts of Radix Paeoniae Rubra, 6-15 parts of Achyranthes bidentata, 3-15 parts of Salvia miltiorrhiza, 6-9 parts of Citrus aurantium, 3-10 parts of platycodon grandiflorum, 6-15 parts of Corydalis 6-15, woody 2 ~12 parts, 3~6 parts of licorice, 6~15 parts of raw land.
优选的,一种用于治疗胸壁挫伤、肋骨骨折的中药组合物,由以下重量份数的组分组成:柴胡15份、桃仁12份、红花9份、当归尾9份、川芎12份、赤芍12份、牛膝12份、丹参12份、枳壳9份、桔梗10份、延胡索15份、木香12份、甘草6份、生地12份。Preferably, a traditional Chinese medicine composition for treating chest wall contusions and rib fractures consists of the following components in parts by weight: 15 parts of Bupleurum bupleuri, 12 parts of peach kernels, 9 parts of safflower, 9 parts of angelica tail, and 12 parts of Chuanxiong , 12 parts of red peony root, 12 parts of Achyranthes bidentata, 12 parts of salvia miltiorrhiza, 9 parts of Citrus aurantii, 10 parts of bellflower, 15 parts of yanhusuo, 12 parts of woody fragrance, 6 parts of licorice, and 12 parts of raw land.
本发明的中药组合物中,各组分中药的药性药效如下:In the Chinese medicine composition of the present invention, the properties and efficacy of each component Chinese medicine are as follows:
柴胡:为伞形科柴胡属植物柴胡或狭叶柴胡的根;含有挥发油如邻甲氧基苯酚、庚内酯、辛内酯、癸内酯、丁香油酚、十一烷酸内酯等,还含有皂苷类如柴胡皂苷、乙酰柴胡皂苷,黄酮类如芦丁、槲皮素等有效成分。苦、辛,微寒,归肝、胆经;功效为解表退热,疏肝解郁,升举阳气;主治外感发热,寒热往来,疟疾,肝郁胁痛乳胀,头痛头眩,月经不调,气虚下陷之脱肛、子宫垂落、胃下垂。现代药理学研究表明,柴胡具有抗炎、解热、镇静、镇痛、镇咳、保肝、护胃、降血脂、抗菌抗病毒、抗肿瘤、促进代谢等作用。Bupleurum: the root of Bupleurum or Bupleurum angustifolia of the genus Bupleurum in the Umbelliferae family; contains volatile oils such as o-methoxyphenol, enantholactone, capryllactone, decanolactone, eugenol, undecanoic acid It also contains saponins such as saikosaponin, acetyl saikosaponin, flavonoids such as rutin, quercetin and other active ingredients. Bitter, pungent, slightly cold, returns to the liver and gallbladder meridian; the effect is to relieve the exterior and reduce fever, soothe the liver and relieve stagnation, and elevate yang qi; it is mainly used to treat fever caused by exogenous factors, alternating cold and heat, malaria, liver stagnation, hypochondriac pain, breast distension, headache, dizziness, Irregular menstruation, prolapse of the anus, prolapse of the uterus, and gastroptosis due to qi deficiency. Modern pharmacological studies have shown that Bupleurum has anti-inflammatory, antipyretic, sedative, analgesic, antitussive, liver-protecting, stomach-protecting, blood-lipid-lowering, anti-bacterial, anti-viral, anti-tumor, and metabolism-promoting effects.
桃仁:为蔷薇科桃属植物桃或山桃的种子;含有苦杏仁苷、野樱苷、甾醇类、有机酸类、蛋白质等有效成分。性苦、甘、平,归心、肝、大肠经。功效为活血祛瘀,润肠通便;主治痛经,血滞经闭,产后瘀滞腹痛,癓瘕结块,跌打损伤,淤血肿痛,肺痈,肠痈,肠燥便秘。现代药理学研究表明,桃仁具有促进循环系统功能、抗凝血和抗血栓、抗炎、止咳祛痰、抗肿瘤等作用。Peach kernel: It is the seed of peach or mountain peach, a plant belonging to the family Rosaceae; it contains amygdalin, prunin, sterols, organic acids, protein and other active ingredients. Bitter in nature, sweet, flat, Guixin, Liver, Large Intestine Channel. Efficacy is promoting blood circulation and removing blood stasis, moistening bowel and defecating; mainly treating dysmenorrhea, amenorrhea due to stagnation of blood, postpartum stagnant abdominal pain, lumps in the abdomen, bruises, congestion, swelling and pain, lung abscess, intestinal abscess, intestinal dryness and constipation. Modern pharmacological research shows that peach kernel has the functions of promoting circulatory system function, anticoagulation and antithrombotic, anti-inflammatory, cough and expectorant, anti-tumor and so on.
红花:为菊科红花属植物红花的花;含有红花苷、前红花苷、红花黄色素、红花明苷等黄酮类化合物,还含有绿原酸、咖啡酸、马鞭烯酮及16种氨基酸等有效成分。性辛、温,归心、肝经;功效为活血通经,祛瘀止痛;主治血瘀经闭,痛经,产后瘀阻腹痛,胸痹心痛,癓瘕积聚,跌打损伤,关节疼痛,中风偏瘫,斑疹。现代药理学研究表明,红花具有增强心血管系统功能、抗凝血、降血脂、增强缺氧耐受能力、免疫活性及抗炎的作用。Safflower: It is the flower of safflower of the genus Safflower in the Compositae family; it contains flavonoids such as safflower glycosides, prosafflower glycosides, safflower yellow pigment, and safflower glycosides, as well as chlorogenic acid, caffeic acid, and verbene Active ingredients such as ketones and 16 kinds of amino acids. Spicy, warm, heart-guiding, liver meridian; effects of promoting blood circulation, dispelling blood stasis and relieving pain; mainly treating blood stasis amenorrhea, dysmenorrhea, postpartum abdominal pain due to blood stasis, chest obstruction and heart pain, accumulation of lumps, bruises, joint pain, stroke and hemiplegia , macula. Modern pharmacological studies have shown that safflower has the functions of enhancing cardiovascular system function, anticoagulation, lowering blood fat, enhancing hypoxia tolerance, immune activity and anti-inflammation.
当归尾:为中药当归的尾部;表面黄棕色至棕褐色,具纵皱纹及横长皮孔,具环纹。具有活血祛瘀的功效,治疗经闭不通及淤血积滞肿痛的病症。Angelica tail: the tail of the traditional Chinese medicine Angelica sinensis; the surface is yellowish brown to tan, with longitudinal wrinkles and horizontally long lenticels, with ring patterns. It has the effect of promoting blood circulation and removing blood stasis, and can treat the symptoms of amenorrhea and stagnant swelling and pain due to congestion.
川芎:为伞形科藁本属植物川芎的根茎;含有川芎嗪、黑麦草碱、川芎哚、藁本内酯、川芎萘呋内酯等多种内酯,还含有酚酸类、挥发油类等多种有效成分。性辛、温,归肝、胆、心包经;功效为活血祛瘀,行气开郁,祛风止痛;主治月经不调,经闭痛经,产后瘀滞腹痛,癓瘕肿块,胸胁疼痛,头痛眩晕,风寒湿痹,跌打损伤,痈疽疮疡。现代药理学研究表明,川芎具有增强心血管系统功能(如扩张血管、抑制高血压、抗心肌缺血和再灌注损伤及对脑缺血的保护作用等)、增强血液系统功能、增强泌尿和免疫系统功能、抗肿瘤、抗放射等作用。Ligusticum Chuanxiong: It is the rhizome of Ligusticum chuanxiong in Umbelliferae; it contains ligustrazine, loline, chuanxiongdole, ligustilide, chuanxiong nafurolide and other lactones, as well as phenolic acids, volatile oils, etc. Various active ingredients. Hot and warm in nature, it returns to the liver, gallbladder and pericardium meridian; the effect is to promote blood circulation and remove blood stasis, promote qi circulation to relieve stagnation, dispel wind and relieve pain; it is mainly used to treat irregular menstruation, amenorrhea dysmenorrhea, postpartum stagnant abdominal pain, lumps in the abdomen, chest and hypochondriac pain, Headache and dizziness, wind-cold-damp arthralgia, bruises, carbuncle sores. Modern pharmacological studies have shown that Rhizoma Chuanxiong can enhance the function of the cardiovascular system (such as dilating blood vessels, inhibiting high blood pressure, resisting myocardial ischemia and reperfusion injury, and protecting against cerebral ischemia, etc.), enhancing blood system function, enhancing urinary and immune function System function, anti-tumor, anti-radiation and other effects.
赤芍:为芍药科芍药属植物芍药、川芍药的根;含有单萜类如芍药苷,有机酸类如苯甲酸、没食子酸,儿茶素、谷甾醇等有效成分。性苦,微寒;归肝、脾经。功效为清热凉血,活血祛瘀;主治温毒发斑,吐血衄血,肠风下血,目赤肿痛,痈肿疮疡,闭经,痛经,崩带淋浊,瘀滞胁痛,疝瘕积聚,跌扑损伤。现代药理学研究表明,赤芍具有抗血栓形成及抗血小板聚集、抗动脉硬化、促进心血管系统功能、抗肿瘤、保肝等作用。Radix Paeoniae Rubra: It is the root of Radix Paeoniae Rubra and Radix Paeoniae Rubra, containing monoterpenoids such as paeoniflorin, organic acids such as benzoic acid, gallic acid, catechin, sitosterol and other active ingredients. Bitter in nature, slightly cold; Return liver, spleen meridian. Efficacy is clearing away heat and cooling blood, promoting blood circulation and removing blood stasis; mainly treating warm toxins and spots, vomiting blood and epistaxis, intestinal wind and blood, red eyes and swelling pain, carbuncle sores, amenorrhea, dysmenorrhea, metrorrhagia and stranguria, stasis and hypochondriac pain, hernia Lump accumulation, injury from falling. Modern pharmacological studies have shown that Radix Paeoniae Rubra has anti-thrombosis, anti-platelet aggregation, anti-arteriosclerosis, promotion of cardiovascular system function, anti-tumor, liver protection and other effects.
牛膝:为苋科牛膝属植物牛膝的根;含有三萜皂苷如牛膝皂苷、人参皂苷、竹节参皂苷等,还含有多糖、甾酮类、氨基酸、蛋白质等多种有效成分。性苦、酸、平,归肝、肾经;功效为补肝肾,强筋骨,活血通经,引血(火)下行,利尿通淋;主治腰膝酸痛,下肢痿软,血滞经闭,痛经,产后血瘀腹痛,癓瘕,胞衣不下,热淋,血淋,跌打损伤,痈肿恶疮,咽喉肿痛。现代药理学研究表明,牛膝具有镇痛抗炎、提高心血管及呼吸系统功能、抗生育、降血糖、提高免疫系统功能、延缓衰老、抗肿瘤的作用。本发明的中药组合物中,所述牛膝为川牛膝。Achyranthes bidentata: It is the root of Achyranthes bidentata in the family Amaranthaceae; it contains triterpenoid saponins such as achyranthes saponins, ginsenosides, and bamboo ginseng saponins, as well as polysaccharides, sterones, amino acids, proteins and other active ingredients. Bitter, sour, flat, returns to the liver and kidney meridian; the effect is to nourish the liver and kidney, strengthen the bones and muscles, promote blood circulation and stimulate the menstrual flow, induce blood (fire) to descend, diuresis and relieve stranguria; mainly treat waist and knee pain, flaccidity and softness of lower limbs, amenorrhea due to stagnation of blood , Dysmenorrhea, postpartum blood stasis, abdominal pain, lump in the abdomen, retained clothes, hot stranguria, stranguria with blood, bruises, carbuncle, malignant sore, sore throat. Modern pharmacological studies have shown that Achyranthes bidentata has the functions of analgesia and anti-inflammation, improving cardiovascular and respiratory system functions, anti-fertility, lowering blood sugar, improving immune system functions, delaying aging and anti-tumor. In the traditional Chinese medicine composition of the present invention, the Achyranthes bidentata is Chuan Achyranthes bidentata.
丹参:为唇形科鼠尾草属植物丹参的根;含有丹参酮、丹参酮基内酯、隐丹参酮、异丹参酮等醌类化合物,还含有水溶性酚酸类化合物如丹参酚酸、原儿茶醛等有效成分。性苦,微寒,归心、包心、肝经;功效为活血祛瘀,调经止痛,除烦安神,凉血消痈;主治妇女月经不调,痛经,闭经,产后瘀滞腹痛,心腹疼痛,癓瘕积聚,热痹肿痛,跌打损伤,热入营血,烦躁不安,心烦失眠,痈疮肿毒。现代药理学研究表明,丹参具有增强心脑血管系统功能、降血脂和抗动脉粥样硬化、抗凝及抗血栓、耐缺氧、增强免疫系统功能、抗炎及抗过敏、保肝护肝、抗胃溃疡、改善肾功能及抗氧化等作用。Salvia miltiorrhiza: the root of Salvia miltiorrhiza in the Lamiaceae family; it contains quinone compounds such as tanshinone, tanshinone lactone, cryptotanshinone, and isotanshinone, as well as water-soluble phenolic compounds such as salvianolic acid and protocatechualdehyde and other active ingredients. Bitter in nature, slightly cold, Guixin, Baoxin, Liver Meridian; the effect is promoting blood circulation and dispelling blood stasis, regulating menstruation and relieving pain, relieving restlessness and tranquilizing the nerves, cooling blood and eliminating carbuncle; mainly treating women's irregular menstruation, dysmenorrhea, amenorrhea, postpartum stagnant abdominal pain, trusted subordinate's pain, Accumulation of lumps in the abdomen, heat numbness and pain, bruises, heat entering the camp and blood, irritability, upset and insomnia, carbuncle and sore swelling. Modern pharmacological research shows that Salvia miltiorrhiza can enhance the function of cardiovascular and cerebrovascular systems, lower blood fat and resist atherosclerosis, anticoagulant and antithrombotic, resist hypoxia, enhance immune system function, anti-inflammation and anti-allergy, protect liver and liver, Anti-gastric ulcer, improve kidney function and anti-oxidation effects.
枳壳:为芸香科柑橘属植物酸橙及其栽培品未成熟的果实;含有黄酮类如橙皮苷、生物碱、柠檬苦素类等有效成分;性苦、酸,温,归肺、脾、胃、大肠经。功效为理气宽胸,行滞消积;主治胸膈带酸,胁肋胀痛,食积不化,脘腹胀满,下痢后重,子宫脱垂。现代药理学研究证明枳壳具有增强心血管系统功能、促进胃肠等作用。Fructus aurantium: the immature fruit of sour orange and its cultivars of the citrus plant of Rutaceae; it contains flavonoids such as hesperidin, alkaloids, limonoids and other active ingredients; it is bitter, sour, warm, and returns to the lungs and spleen , stomach, large intestine channel. The efficacy is to regulate qi and broaden the chest, stagnant movement and eliminate stagnation; it mainly treats soreness in the chest and diaphragm, distending pain in the flanks, inability to dissolve food accumulation, fullness in the abdomen, heavy diarrhea after diarrhea, and uterine prolapse. Modern pharmacological studies have proved that Fructus Aurantii has the functions of enhancing cardiovascular system and promoting gastrointestinal function.
桔梗:为桔梗科桔梗属植物桔梗的根;含有桔梗皂苷、皂苷元、甾醇类等有效成分。味苦,性平,归肺经。有开宣肺气,祛痰排脓之功效。用于治疗外感咳嗽,咽喉肿痛,肺痈吐痰,胸满胁痛,痢疾腹痛等病。《珍珠囊》记载:“与甘草通行,为舟楫之剂”。桔梗具有多方面的药理作用,其中对巨噬细胞的调控作用是最重要的一环,是桔梗抗炎、抗肿瘤、抗病原微生物的作用机制之一。Platycodon grandiflorum: the root of Platycodon grandiflorum, a plant of the genus Campanulaceae, containing platycodon saponins, saponins, sterols and other active ingredients. Bitter in the mouth, flat in nature, returns lung meridian. It has the effect of opening lung qi, eliminating phlegm and discharging pus. For the treatment of exogenous cough, sore throat, lung abscess, spitting, chest fullness and hypochondriac pain, dysentery and abdominal pain and other diseases. "Pearl Sac" records: "passing with licorice is an agent for boats". Platycodon grandiflorum has many pharmacological effects, among which the regulation of macrophages is the most important part, and it is one of the mechanism of action of platycodon grandiflorum for anti-inflammation, anti-tumor and anti-pathogenic microorganisms.
延胡索:为罂粟科紫堇属植物延胡索的块茎;含有生物碱如紫堇碱、原阿片碱、四氢黄连碱等有效成分。性辛、苦、温,归肝、胃、心、肺、脾经。功效为活血,散瘀,理气,止痛;主治心腹腰膝诸痛,月经不调,症瘕,崩中,产后血晕,恶露不尽,跌打损伤。现代药理学研究证明,延胡索具有止痛镇痛、催眠、镇静、安定、抗肿瘤、促进消化系统功能、促进心血管系统功能等作用。Corydalis Corydalis: the tuber of Corydalis Corydalis in the family Papaveraceae; it contains alkaloids such as cordyline, protopine, and tetrahydro-bertisine. Pungent, bitter, and warm in nature, it returns to the Liver, Stomach, Heart, Lung, and Spleen Channels. Efficacy is promoting blood circulation, dispelling blood stasis, regulating qi, and relieving pain; mainly treating confidants' waist and knee pain, irregular menstruation, lump in the abdomen, metrorrhagia, postpartum haemorrhage, lochia, and bruises. Modern pharmacological studies have proved that Yanhusuo has the functions of analgesia, hypnosis, sedation, stability, anti-tumor, promotion of digestive system function, and promotion of cardiovascular system function.
木香:异名广木香,为菊科云木香属植物木香的根;根油含内酯类化合物、挥发性成分及多种氨基酸等有效成分;性辛、苦,温,归脾、胃、肝、肺经。功效为行气止痛,调中导滞;主治胸胁胀满,脘腹胀痛,呕吐泄泻,痢疾后重。现代药理学研究证明,木香具有促进胃肠道、降压、抗炎、镇痛、降血糖等作用。Muxiang: a synonym of Guangmuxiang, which is the root of the plant Muxiang in the family Asteraceae; the root oil contains active ingredients such as lactone compounds, volatile components, and various amino acids; it is pungent, bitter, warm, and returns to the spleen , stomach, liver, lung meridian. Efficacy is promoting qi and relieving pain, regulating the middle and guiding stagnation; mainly treating fullness in the chest and hypochondrium, abdominal distension and pain, vomiting and diarrhea, and post-dysentery. Modern pharmacological studies have proved that woody incense has the effects of promoting the gastrointestinal tract, lowering blood pressure, anti-inflammatory, analgesic, and lowering blood sugar.
甘草:为豆科甘草属植物甘草、光果甘草、胀果甘草的根及根茎;含有三萜皂苷、黄酮类化合物、香豆素类化合物、生物碱类及多糖等多种有效成分;甘、平,归脾、胃、心、肺经。功效为和中缓急,润肺,解毒,调和诸药;主治脾胃虚弱,倦怠食少,腹痛便溏,四肢挛急疼痛,心悸,脏燥,肺痿咳嗽,咽喉肿痛,痈疮肿毒,小儿胎毒及药物、食物中毒。现代药理学研究证明甘草具有抗微生物、提高心血管系统功能、促进消化、保肝、抗炎、镇痛、祛痰、提高免疫系统功能、抗肿瘤、抗突变、解毒、抗氧化等作用。Licorice: the roots and rhizomes of Glycyrrhiza glabra, Glycyrrhizae glabra, and Glycyrrhiza inflate; it contains various active ingredients such as triterpenoid saponins, flavonoids, coumarins, alkaloids and polysaccharides; sweet, Flat, returns spleen, stomach, heart, lung channel. Efficacy is to neutralize the emergency, moisturize the lungs, detoxify, and reconcile various medicines; it is mainly used to treat weakness of the spleen and stomach, fatigue, lack of food, abdominal pain and loose stools, acute pain in the limbs, palpitations, dryness of the lungs, lung flaccidity and cough, sore throat, carbuncles, swollen toxins, Fetal poisoning in children and drug and food poisoning. Modern pharmacological studies have proved that licorice has antimicrobial, improving cardiovascular system function, promoting digestion, protecting liver, anti-inflammatory, analgesic, expectorant, improving immune system function, anti-tumor, anti-mutation, detoxification, and anti-oxidation.
生地:为玄参科植物地黄的块根;甘,寒,归心、肝、肾经。含有谷甾醇与甘露醇、地黄素、生物碱、脂肪酸、葡萄糖与维生素A等有效成分。具有清热凉血、益阴生津之功效,用于温热病热入营血,壮热神昏,口干舌绛。Habitat: the root of Radix Rehmanniae of Scrophulariaceae; sweet, cold, Guixin, Liver, Kidney meridians. Contains effective ingredients such as sitosterol and mannitol, rehmanthin, alkaloids, fatty acids, glucose and vitamin A. It has the effects of clearing away heat and cooling blood, benefiting yin and promoting body fluid, and is used for febrile diseases with heat entering the camp and blood, strong heat, dizziness, dry mouth and tongue.
本发明的中药组合物中,桃仁,破血逐瘀、润燥滑肠;红花,活血通经、祛瘀止痛;当归尾,活血止痛、润肠通便、补血调经;川芎,活血行气、祛风止痛;赤芍,活血调经、祛瘀止痛、清肝明目、消痈散肿;牛膝,活血祛瘀、强筋骨、利关节、引血下行、利尿通淋;丹参,活血祛瘀、活血消肿、养血安神。桔梗,宣肺祛痰、利咽止痛、排脓消痈;甘草,补中益气、清热解毒、祛痰止咳、缓急止痛。延胡索,活血行气止痛;柴胡,透表泄热、疏肝解郁、升阳举陷,用于退热;木香,行气止痛、健胃消食。枳壳,破气消积、下气通便;生地,清热凉血、凉血止血、养阴生津。诸药合用,活血与行气相伍、既行血分瘀滞,又解气分郁结;祛痰与养血同施,则活血而无耗血之虑、行气又无伤阴之弊,升降兼顾,既能升达清阳,又佐降泄下行,使气血和调。In the traditional Chinese medicine composition of the present invention, peach kernel, dispels blood stasis, moistens dryness and smooths intestines; safflower, promotes blood circulation and stimulates menstrual flow, dispels blood stasis and relieves pain; Angelica tail, promotes blood circulation and relieves pain, laxes bowels, nourishes blood and regulates menstruation; Chuanxiong, promotes blood circulation and promotes Qi , expelling wind and relieving pain; red peony root, promoting blood circulation and regulating menstruation, dispelling blood stasis and relieving pain, clearing liver and improving eyesight, eliminating carbuncle and dissipating swelling; Blood stasis, promoting blood circulation to reduce swelling, nourishing blood to calm the nerves. Platycodon grandiflorum, clearing lung and eliminating phlegm, relieving sore throat and relieving pain, draining pus and eliminating carbuncle; Licorice root, invigorating the middle and replenishing qi, clearing heat and detoxification, eliminating phlegm and relieving cough, relieving spasm and relieving pain. Corydalis Corydalis, promoting blood circulation and promoting qi to relieve pain; Bupleurum, expelling heat from the surface, soothing the liver and relieving stagnation, raising yang and lifting depression, used for reducing fever; woody fragrance, promoting qi and relieving pain, invigorating the stomach and eliminating food. Citrus aurantium, dispels qi and eliminates stagnation, lowers qi and laxative; Shengdi, clears heat and cools blood, cools blood to stop bleeding, nourishes yin and promotes body fluid. Combined use of various medicines, promoting blood circulation and promoting qi together, not only promoting blood stasis, but also relieving stagnation of qi; expelling phlegm and nourishing blood at the same time, promoting blood circulation without worrying about blood consumption, promoting qi without harming yin, and taking care of ascending and descending , it can not only ascend to Qingyang, but also assist in descending and venting, so as to harmonize Qi and blood.
本发明的用于治疗胸壁挫伤、肋骨骨折的中药组合物,采用柴胡、桃仁、红花、当归尾、川芎、赤芍、牛膝、丹参、枳壳、桔梗、延胡索、木香、甘草、生地这14味中药复配,配方合理,配方中使用的桃仁、红花为君,赤芍、川芎助君,牛膝为臣,改善胸壁挫伤、肋骨骨折肿痛症状,与桔梗、枳壳、柴胡成份相配伍,理气行滞,疏肝解郁,起到综合调理、标本兼治的目的;配方中使用的中药原料来源广泛、成本低廉,用于治疗胸壁挫伤、肋骨骨折疗效确切。The traditional Chinese medicine composition for the treatment of chest wall contusion and rib fracture of the present invention uses Bupleurum chinensis, peach kernel, safflower, angelica tail, chuanxiong, red peony root, achyranthes bidentata, salvia miltiorrhiza, aurantium aurantii, platycodon grandiflorum, corydalis, woody fragrance, licorice, The combination of 14 traditional Chinese medicines of Shengdi has a reasonable formula. The peach kernel and safflower used in the formula are the king, the red peony root and Chuanxiong are the king, and the achyranthes bidentata is the minister. It can improve the symptoms of chest wall contusion and rib fracture swelling and pain. The components of Bupleuri are compatible to regulate qi and promote stagnation, soothe the liver and relieve stagnation, and achieve the purpose of comprehensive conditioning and treating both symptoms and root causes; the raw materials of traditional Chinese medicine used in the formula have a wide range of sources and low cost, and are effective in treating chest wall contusion and rib fracture.
一种用于治疗胸壁挫伤、肋骨骨折的中药制剂,主要由以下重量份数的原料制成:柴胡3~15份、桃仁6~12份、红花3~9份、当归尾6~15份、川芎3~12份、赤芍6~12份、牛膝6~15份、丹参3~15份、枳壳6~9份、桔梗3~10份、延胡索6~15份、木香2~12份、甘草3~6份、生地6~15份。A traditional Chinese medicine preparation for treating chest wall contusion and rib fracture, mainly made of the following raw materials in parts by weight: 3-15 parts of Bupleurum bupleurum, 6-12 parts of peach kernel, 3-9 parts of safflower, 6-15 parts of angelica tail 3-12 parts of Chuanxiong, 6-12 parts of Radix Paeoniae Rubra, 6-15 parts of Achyranthes bidentata, 3-15 parts of Salvia miltiorrhiza, 6-9 parts of Citrus aurantium, 3-10 parts of platycodon grandiflorum, 6-15 parts of Corydalis 6-15, woody 2 ~12 parts, 3~6 parts of licorice, 6~15 parts of raw land.
优选的,一种用于治疗胸壁挫伤、肋骨骨折的中药制剂,主要由以下重量份数的原料制成:柴胡15份、桃仁12份、红花9份、当归尾9份、川芎12份、赤芍12份、牛膝12份、丹参12份、枳壳9份、桔梗10份、延胡索15份、木香12份、甘草6份、生地12份。Preferably, a traditional Chinese medicine preparation for treating chest wall contusion and rib fracture is mainly made of the following raw materials in parts by weight: 15 parts of Bupleurum bupleuri, 12 parts of peach kernel, 9 parts of safflower, 9 parts of angelica tail, and 12 parts of Chuanxiong , 12 parts of red peony root, 12 parts of Achyranthes bidentata, 12 parts of salvia miltiorrhiza, 9 parts of Citrus aurantii, 10 parts of bellflower, 15 parts of yanhusuo, 12 parts of woody fragrance, 6 parts of licorice, and 12 parts of raw land.
所述中药制剂为散剂、胶囊剂、汤剂或丸剂。所述中药制剂的剂型为按照中国药典2010版要求制成的散剂、胶囊剂、汤剂或丸剂;优选为汤剂。The traditional Chinese medicine preparation is powder, capsule, decoction or pill. The dosage form of the traditional Chinese medicine preparation is powder, capsule, decoction or pill prepared according to the requirements of the Chinese Pharmacopoeia 2010 edition; preferably decoction.
一种上述的用于治疗胸壁挫伤、肋骨骨折的中药制剂的制备方法,包括按配方量取原料,两次加水煎煮,合并煎液,即得汤剂。A preparation method of the above-mentioned traditional Chinese medicine preparation for treating chest wall contusion and rib fracture, comprising: taking raw materials according to the formula, adding water for decoction twice, and combining the decoctions to obtain the decoction.
上述制备方法中,将原料药置于容器中,加水至水面高出药面3~5cm,先武火煮沸后改文火,煮沸20min后过滤取煎液;再加水进行第二次煎煮(具体操作同上),合并两次煎液,即得汤剂。In the above preparation method, the raw material medicine is placed in a container, water is added until the water surface is 3-5cm higher than the medicine surface, the fire is first boiled, then the fire is changed to a simmer, and after boiling for 20 minutes, the decoction is obtained by filtering; water is added for the second decoction (specific operation Same as above), combined two decoctions to obtain decoction.
所述汤剂服用时每日一剂,每剂450~550ml,分2~3次饭后服下,10~15日为一个疗程。When the decoction is taken, one dose per day, 450-550 ml per dose, is taken after meals in 2-3 times, and 10-15 days is a course of treatment.
一种上述的用于治疗胸壁挫伤、肋骨骨折的中药制剂的制备方法,包括按配方量取原料,粉碎至100~150目细粉,制得散剂或装胶囊得胶囊剂。A preparation method of the above-mentioned traditional Chinese medicine preparation for treating chest wall contusion and rib fracture, comprising: taking raw materials according to the formula, pulverizing them into fine powders of 100-150 mesh, preparing powders or packing them into capsules to obtain capsules.
一种上述的用于治疗胸壁挫伤、肋骨骨折的中药制剂的制备方法,包括以下步骤:A kind of preparation method of above-mentioned Chinese medicine preparation for the treatment of chest wall contusion, rib fracture, comprises the following steps:
1)按配方量取原料,粉碎并过筛后,灭菌,得粉剂;1) Measure raw materials according to the formula, crush and sieve, sterilize to obtain powder;
2)按照粉剂与中蜜的质量比为100:30的比例,将粉剂与中蜜混合后,加热至65~75℃与开水混合均匀,精练3次后制成丸状,后干燥,即得蜜丸。2) According to the mass ratio of powder and honey in the ratio of 100:30, mix the powder and honey, heat it to 65-75°C and mix it with boiling water evenly, refine it for 3 times, make it into a pellet, and then dry it to get honey pill.
步骤1)中,所述过筛是指过100~150目筛。In step 1), the sieving refers to passing through a 100-150 mesh sieve.
步骤1)中,所述灭菌是在100℃灭菌30min。In step 1), the sterilization is at 100° C. for 30 minutes.
步骤2)中,所述干燥的温度为55~65℃。In step 2), the drying temperature is 55-65°C.
所述精炼3次是指先使一部分药粉粘合成0.5~1.0mm大小的丸芯(起模),再将所得丸芯放入药粉中摇动加大泛制成中丸(成型),最后将中丸制成成品大小使丸剂的表面致密、光洁、色泽一致(盖面)。The said refining 3 times refers to that a part of the medicine powder is first bonded into a ball core with a size of 0.5-1.0mm (moulding), then the obtained ball core is put into the medicine powder, shaken and enlarged to make a middle pill (molding), and finally the middle pill is made into a ball core. The size of the finished product makes the surface of the pill dense, smooth and consistent in color (cover).
本发明的用于治疗胸壁挫伤、肋骨骨折的中药制剂,主要由柴胡、桃仁、红花、当归尾、川芎、赤芍、牛膝、丹参、枳壳、桔梗、延胡索、木香、甘草、生地这14味中药制成,可为散剂、胶囊剂、汤剂或丸剂,用于治疗胸壁挫伤、肋骨骨折疗效显著。其中,汤剂煎煮服用,操作方便;散剂和胶囊剂制作简单,成本低,方便储存与运输;丸剂为蜜丸,患者服用时顺应性较好,工艺简单,成本低,适合大规模工业化生产。The traditional Chinese medicine preparation for the treatment of chest wall contusion and rib fracture of the present invention mainly consists of Bupleurum chinensis, peach kernel, safflower, angelica tail, chuanxiong, red peony root, achyranthes bidentata, salvia miltiorrhiza, citrus aurantium, platycodon grandiflorum, corydalis, woody fragrance, licorice, Shengdi is made from 14 traditional Chinese medicines and can be used as powder, capsule, decoction or pill. It is effective in treating chest wall contusion and rib fracture. Among them, the decoction is easy to operate; the powder and capsule are easy to make, low in cost, and convenient for storage and transportation; the pill is a honeyed pill, which has better compliance when taken by patients, simple process, low cost, and is suitable for large-scale industrial production. .
具体实施方式detailed description
下面结合具体实施例对本发明作进一步的说明。The present invention will be further described below in conjunction with specific examples.
实施例1Example 1
本实施例的用于治疗胸壁挫伤、肋骨骨折的中药组合物,由以下重量的组分组成:柴胡15g、桃仁12g、红花9g、当归尾9g、川芎12g、赤芍12g、牛膝12g、丹参12g、枳壳9g、桔梗10g、延胡索15g、木香12g、甘草6g、生地12g。The traditional Chinese medicine composition for the treatment of chest wall contusion and rib fracture in this embodiment consists of the following components by weight: Bupleurum bupleuri 15g, peach kernel 12g, safflower 9g, angelica tail 9g, chuanxiong 12g, red peony root 12g, achyranthes bidentata 12g , Salvia 12g, Citrus aurantium 9g, Bellflower 10g, Corydalis 15g, Woody 12g, Licorice 6g, Habitat 12g.
本实施例的用于治疗胸壁挫伤、肋骨骨折的中药制剂为汤剂,主要由上述的中药组合物制成。制备方法包括按配方量取中药组合物置于砂罐中,加水使水面高出药面3cm,武火煮沸后改用文火煮沸20min,过滤得煎液;将滤渣加水,水面高出药面3cm,武火煮沸后改用文火煮沸20min,过滤二次煎液,合并两次煎液,即得汤剂。The traditional Chinese medicine preparation for treating chest wall contusion and rib fracture in this embodiment is a decoction, which is mainly made of the above-mentioned traditional Chinese medicine composition. The preparation method comprises: taking the traditional Chinese medicine composition according to the formula and placing it in a sand pot, adding water to make the water surface 3cm higher than the medicinal surface, boiling with a strong fire and switching to a slow fire for 20 minutes, and filtering to obtain a decoction; adding water to the filter residue, making the water surface 3cm higher than the medicinal surface, After boiling, switch to simmering for 20 minutes, filter the second decoction, and combine the two decoctions to obtain the decoction.
所述汤剂服用时每日一剂,每剂450~550ml,分2~3次饭后服下,10日为一疗程。When the decoction is taken, one dose per day, 450-550 ml per dose, is taken after meals in 2-3 times, and 10 days is a course of treatment.
实施例2Example 2
本实施例的用于治疗胸壁挫伤、肋骨骨折的中药组合物,由以下重量的组分组成:柴胡3g、桃仁12g、红花9g、当归尾9g、川芎6g、赤芍6g、牛膝9g、丹参12g、枳壳6g、桔梗5g、延胡索15g、木香10g、甘草6g、生地9g。The traditional Chinese medicine composition for the treatment of chest wall contusion and rib fracture in this example consists of the following components by weight: Bupleurum bupleuri 3g, peach kernel 12g, safflower 9g, angelica tail 9g, chuanxiong 6g, red peony 6g, and achyranthes bidentata 9g , Salvia 12g, Citrus aurantium 6g, Bellflower 5g, Corydalis 15g, Woody 10g, Licorice 6g, Habitat 9g.
本实施例的用于治疗胸壁挫伤、肋骨骨折的中药制剂为散剂,由上述的中药组合物制成。制备方法为:按配方量取中药组合物,粉碎至120目细粉,制得散剂。或者将所得细粉装胶囊得胶囊剂。The traditional Chinese medicine preparation for treating chest wall contusion and rib fracture in this embodiment is a powder made from the above-mentioned traditional Chinese medicine composition. The preparation method is as follows: measure the traditional Chinese medicine composition according to the formula, grind it into 120-mesh fine powder, and prepare the powder. Alternatively, the obtained fine powder is packed into capsules to obtain capsules.
所述胶囊剂的服用方法为:每次2~4g,一日三次。The taking method of the capsule is: 2-4g each time, three times a day.
实施例3Example 3
本实施例的用于治疗胸壁挫伤、肋骨骨折的中药组合物,由以下重量的组分组成:柴胡3g、桃仁12g、红花9g、当归尾9g、川芎9g、赤芍9g、牛膝12g、丹参9g、枳壳6g、桔梗6g、延胡索12g、木香12g、甘草6g、生地6g。The traditional Chinese medicine composition for treating chest wall contusion and rib fracture in this embodiment consists of the following components by weight: Bupleurum bupleuri 3g, peach kernel 12g, safflower 9g, angelica tail 9g, chuanxiong 9g, red peony root 9g, achyranthes bidentata 12g , Salvia 9g, Citrus aurantium 6g, Bellflower 6g, Corydalis 12g, Woody 12g, Licorice 6g, Habitat 6g.
本实施例的用于治疗胸壁挫伤、肋骨骨折的中药组制剂为丸剂,主要由上述的中药组合物制成。制备方法包括以下步骤:The Chinese medicine group preparation for treating chest wall contusion and rib fracture in this embodiment is a pill, which is mainly made of the above-mentioned Chinese medicine composition. The preparation method comprises the following steps:
1)按配方量取上述中药组合物,粉碎并过120目筛后,于100℃灭菌30min,得粉剂;1) Measure the above-mentioned traditional Chinese medicine composition according to the formula, crush it and pass it through a 120-mesh sieve, and then sterilize it at 100°C for 30 minutes to obtain a powder;
2)按照粉剂与中蜜的质量比为100:30的比例,将粉剂与中蜜混合后,加热至70℃后与开水混合均匀,精练3次后制成重量为0.3g的丸状,后60℃干燥,即得蜜丸。2) According to the mass ratio of the powder and the honey in the ratio of 100:30, mix the powder and the honey, heat it to 70°C, mix it with boiling water evenly, and make it into a pellet with a weight of 0.3g after scouring for 3 times. Dry at 60°C to obtain honeyed pills.
所述蜜丸的服用方法为:每次3~6g,一日二次。The taking method of the honeyed pill is: 3-6g each time, twice a day.
实施例4-8的用于治疗胸壁挫伤、肋骨骨折中药组合物的配方如表1所示。Table 1 shows the formulations of the traditional Chinese medicine compositions used in the treatment of chest wall contusions and rib fractures in Examples 4-8.
表1实施例4-8的中药组合物的配方The formula of the Chinese medicine composition of table 1 embodiment 4-8
实施例4-8的用于治疗胸壁挫伤、肋骨骨折的中药制剂可为汤剂、散剂(或胶囊剂)、丸剂,各制剂的制备方法分别同实施例1、实施例2或实施例3。The traditional Chinese medicine preparation for the treatment of chest wall contusion and rib fracture of embodiment 4-8 can be decoction, powder (or capsule), pill, and the preparation method of each preparation is respectively the same as embodiment 1, embodiment 2 or embodiment 3.
临床试验结果如下:The clinical trial results are as follows:
(1)一般资料(1) General Information
所有胸壁挫伤、肋骨骨折入选病例为轻度、中度外科患者,排除重度患者、孕妇、有严重胃十二指肠溃疡病史患者以及有严重脑、肝、肾等脏器病变者、阴虚火旺,上盛下虚及气弱之人。共入选61例,其中男32例,女29例,年龄40~75岁。61例入选病例中,其中由暴力外伤引起的胸壁挫伤、肋骨骨折为55例,外力及老年骨质疏松为主要原因引起的为6例。All chest wall contusions and rib fractures are selected as mild and moderate surgical patients, excluding severe patients, pregnant women, patients with a history of severe gastroduodenal ulcer, and those with severe brain, liver, kidney and other organ lesions, and those with yin deficiency and hyperactivity of fire , people with deficiency in the upper part and weak Qi in the lower part. A total of 61 cases were selected, including 32 males and 29 females, aged 40 to 75 years. Among the 61 selected cases, 55 cases were chest wall contusions and rib fractures caused by violent trauma, and 6 cases were caused by external force and senile osteoporosis.
(2)研究方法(2) Research methods
61例入选患者分为两组,治疗组31例,对照组30例。The 61 selected patients were divided into two groups, 31 cases in the treatment group and 30 cases in the control group.
治疗组服用本发明实施例1的中药组合物制成的汤剂,一日二次,每日一剂,饭后服用。The treatment group took the decoction made from the traditional Chinese medicine composition of Example 1 of the present invention, twice a day, one dose a day, after meals.
对照组给予药物止痛,促进康复营养药物:药物活血化瘀,一日一次口服伤科跌打丸。The control group was given drugs to relieve pain and nutritional drugs to promote recovery: drugs to promote blood circulation and remove blood stasis, and oral Shangke Dieda pills once a day.
两组在治疗期间中其他内科病症可继续照常治疗。15天为1个疗程。During the treatment period, other medical diseases in the two groups can continue to be treated as usual. 15 days is a course of treatment.
(3)疗效判定标准(3) Judgment criteria for curative effect
治愈:胸壁挫伤、肋骨骨折愈合;显效:胸壁挫伤、肋骨骨折症状明显减轻;有效:胸壁挫伤、肋骨骨折症状改善;无效:胸壁挫伤、肋骨骨折无改善。Cured: chest wall contusion and rib fracture healed; markedly effective: symptoms of chest wall contusion and rib fracture were significantly relieved; effective: symptoms of chest wall contusion and rib fracture improved; ineffective: chest wall contusion and rib fracture did not improve.
(4)研究结果(4) Research results
治疗90天后,两组疗效比较结果如表2所示。After 90 days of treatment, the curative effect comparison results of the two groups are shown in Table 2.
表2两组疗效比较结果Table 2 Comparison of the curative effects of the two groups
(5)结论(5 Conclusion
治疗30天后,治疗组对胸壁挫伤、肋骨骨折的总有效率为93.54%,显著高于对照组的66.67%(P<0.01)。实验结果表明,本发明的中药组合物对胸壁挫伤、肋骨骨折具有显著的疗效。服用本发明的中药组合物未出现肝肾功能损害等不良反应,表明本发明中药组合物具有较好的安全性。After 30 days of treatment, the total effective rate of chest wall contusion and rib fracture in the treatment group was 93.54%, which was significantly higher than 66.67% in the control group (P<0.01). Experimental results show that the traditional Chinese medicine composition of the invention has significant curative effect on chest wall contusion and rib fracture. Taking the traditional Chinese medicine composition of the present invention has no adverse reactions such as liver and kidney function damage, indicating that the traditional Chinese medicine composition of the present invention has better safety.
实验例2~8的胸壁挫伤、肋骨骨折患者依次分别服用实施例2~8的胶囊剂、汤剂或蜜丸,具体实验方法同实验例1,治疗效果见表2:The patients with chest wall contusion and rib fracture of Experimental Examples 2-8 took the capsules, decoctions or honeyed pills of Embodiments 2-8 respectively in turn. The specific experimental method was the same as that of Experimental Example 1. The therapeutic effect is shown in Table 2:
表2实验例2~8疗效的比较结果Table 2 Comparative results of experimental examples 2 to 8 curative effects
结论:治疗20天后,治疗组对胸壁挫伤、肋骨骨折的总有效率为78.95~89.74%,显著高于对照组的60.00~65.71%(P<0.01)。实验结果表明,本发明的中药组合物对胸壁挫伤、肋骨骨折具有显著的疗效;服用本发明的中药组合物未出现肝肾功能损害等不良反应,表明本发明中药组合物具有较好的安全性。Conclusion: After 20 days of treatment, the total effective rate of chest wall contusion and rib fracture in the treatment group was 78.95-89.74%, significantly higher than that of the control group (60.00-65.71% (P<0.01). Experimental results show that the Chinese medicine composition of the present invention has significant curative effect on chest wall contusion and rib fracture; adverse reactions such as liver and kidney function damage do not occur after taking the Chinese medicine composition of the present invention, showing that the Chinese medicine composition of the present invention has better safety .
典型病例Typical cases
典型病例1:广东省佛山市赵先生,55岁,肋骨骨折,服用三七制剂等中药活血化瘀治疗无效,在外科常规治疗的同时,一日2次服用采用本发明实施例4的中药组合物制成的汤剂30天后,肋骨骨折症状改善,服用90天后肋骨骨折愈合。Typical case 1: Mr. Zhao, 55 years old, from Foshan City, Guangdong Province, had a rib fracture, and the treatment of traditional Chinese medicine such as Panax notoginseng preparation for promoting blood circulation and removing blood stasis was ineffective. He took the traditional Chinese medicine combination of Example 4 of the present invention twice a day at the same time as conventional surgical treatment After 30 days of taking the decoction made from the decoction, the symptoms of rib fractures improved, and after taking it for 90 days, the rib fractures healed.
典型病例2:河南省宜阳县刘女士,48岁,胸壁挫伤,多次经针炙、中药活血化瘀等治疗疗效差,一日2次服用采用本发明实施例5的中药组合物制成的汤剂20天后胸壁挫伤症状改善。Typical case 2: Ms. Liu from Yiyang County, Henan Province, 48 years old, suffered from chest wall contusion. The therapeutic effects of acupuncture and moxibustion, traditional Chinese medicine for promoting blood circulation and removing blood stasis were poor. She took the traditional Chinese medicine composition of Example 5 of the present invention twice a day. The decoction of chest wall contusion symptoms improved after 20 days.
典型病例3:广东省高明市张先生,61岁,肋骨骨折,服用三七制剂等中药活血化瘀治疗无效,在外科常规治疗的同时,每次2~4g,一日3次服用采用本发明实施例2的中药组合物制成的胶囊剂30天后,肋骨骨折症状改善,服用90天后肋骨骨折愈合。Typical case 3: Mr. Zhang, 61 years old, from Gaoming City, Guangdong Province, suffered a rib fracture. The treatment of traditional Chinese medicine such as Panax notoginseng preparation for promoting blood circulation and removing blood stasis was ineffective. At the same time of conventional surgical treatment, he took 2-4g each time, 3 times a day, using the present invention After 30 days of capsules made from the traditional Chinese medicine composition of Example 2, the rib fracture symptoms improved, and the rib fracture healed after taking it for 90 days.
典型病例4:河南省洛阳市田先生,70岁,胸壁挫伤,经针炙、中药活血化瘀等治疗疗效差,在常规治疗的同时,每次2~4g,一日3次服用采用本发明实施例6的中药组合物制成的胶囊剂20天后,胸壁挫伤症状明显改善。Typical case 4: Mr. Tian, 70 years old, from Luoyang City, Henan Province, suffered chest wall contusion, and the curative effect was poor after acupuncture, traditional Chinese medicine for promoting blood circulation and removing blood stasis. In addition to conventional treatment, he took 2-4g each time, 3 times a day, and adopted the present invention After 20 days of capsules made from the traditional Chinese medicine composition of Example 6, the symptoms of chest wall contusion were significantly improved.
典型病例5:广西省南宁市李女士,55岁,肋骨骨折,服用三七制剂等中药活血化瘀治疗无效,在外科常规治疗的同时,每次3~6g,一日2次服用采用本发明实施例3的中药组合物制成的丸剂30天后,肋骨骨折症状改善,服用90天后肋骨骨折愈合。Typical case 5: Ms. Li, Nanning City, Guangxi Province, 55 years old, suffered a rib fracture, and her treatment of promoting blood circulation and removing blood stasis with traditional Chinese medicine such as Panax notoginseng preparation was ineffective. At the same time of routine surgical treatment, 3-6g each time, twice a day, used the present invention After 30 days of the pill made from the traditional Chinese medicine composition of Example 3, the rib fracture symptoms improved, and the rib fracture healed after taking it for 90 days.
典型病例7:河南省开封市王女士,60岁,胸壁挫伤,服用中药活血化瘀治疗无效,每次3~6g,一日2次服用采用本发明实施例7的中药组合物制成的丸剂20天后,胸壁挫伤症状改善。Typical case 7: Ms. Wang, Kaifeng City, Henan Province, 60 years old, contusion of the chest wall, taking traditional Chinese medicine to promote blood circulation and remove blood stasis was ineffective, 3-6g each time, twice a day to take the pill made of the traditional Chinese medicine composition of Example 7 of the present invention After 20 days, symptoms of chest wall contusion improved.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510638080.8A CN105232746A (en) | 2015-09-30 | 2015-09-30 | Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating thoracic wall contusion and rib fracture and preparation method of traditional Chinese medicine preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510638080.8A CN105232746A (en) | 2015-09-30 | 2015-09-30 | Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating thoracic wall contusion and rib fracture and preparation method of traditional Chinese medicine preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105232746A true CN105232746A (en) | 2016-01-13 |
Family
ID=55030741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510638080.8A Pending CN105232746A (en) | 2015-09-30 | 2015-09-30 | Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating thoracic wall contusion and rib fracture and preparation method of traditional Chinese medicine preparation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105232746A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105726757A (en) * | 2016-04-29 | 2016-07-06 | 王发堂 | Ginseng stasis-removing blood-promoting traditional Chinese medicine for treating cardio-cerebral stasis |
CN108785421A (en) * | 2017-05-01 | 2018-11-13 | 王晓霞 | A kind of Chinese medicine preparation and its preparation method for treating fracture |
CN118203562A (en) * | 2024-02-18 | 2024-06-18 | 甘肃中医药大学附属医院 | Application of Incarvilone A in preparing external medicine for treating chest wall contusion and pharmaceutical preparation |
-
2015
- 2015-09-30 CN CN201510638080.8A patent/CN105232746A/en active Pending
Non-Patent Citations (4)
Title |
---|
吴建国: "血府逐瘀汤加减治疗肋骨骨折62例", 《湖南中医杂志》 * |
姜其才: "血府逐瘀汤加减治疗胸壁挫伤", 《山东中医杂志》 * |
张加宇等: "血府逐瘀汤治疗肋骨骨折的临床研究", 《中医临床研究》 * |
雷晓丽: "血府逐瘀汤内服加外敷治疗胸壁挫伤临床观察", 《现代中医药》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105726757A (en) * | 2016-04-29 | 2016-07-06 | 王发堂 | Ginseng stasis-removing blood-promoting traditional Chinese medicine for treating cardio-cerebral stasis |
CN108785421A (en) * | 2017-05-01 | 2018-11-13 | 王晓霞 | A kind of Chinese medicine preparation and its preparation method for treating fracture |
CN108785421B (en) * | 2017-05-01 | 2021-07-27 | 王晓霞 | A Chinese medicinal composition for treating fracture and its preparation method |
CN118203562A (en) * | 2024-02-18 | 2024-06-18 | 甘肃中医药大学附属医院 | Application of Incarvilone A in preparing external medicine for treating chest wall contusion and pharmaceutical preparation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104998017A (en) | Traditional Chinese medicine for expelling toxin and nourishing liver and kidney and preparation method thereof | |
CN107929629A (en) | One kind prolongs age and consolidates ball and preparation method thereof | |
CN103432559B (en) | Traditional Chinese medicine composition for treating spanomenorrhea and dysmenorrhea caused by blood stasis and preparation method and application thereof | |
CN104306540B (en) | A kind of treat Chinese medicine preparation of numb limbs and tense tendons and preparation method thereof after brain tumor surgery | |
CN103877247A (en) | Medicine for treating bedsore and preparation method thereof | |
CN105232746A (en) | Traditional Chinese medicine composition and traditional Chinese medicine preparation for treating thoracic wall contusion and rib fracture and preparation method of traditional Chinese medicine preparation | |
CN105497439A (en) | Medicine composition for treating gynecological postoperative low fever | |
CN104922426A (en) | Pharmaceutical composition for treating post gynecologic operation low fever | |
CN105168832A (en) | Medicine for treating liver qi stagnation type mammary gland proliferation | |
CN102552708A (en) | Medicinal composition for calming liver wind | |
CN104524190A (en) | Medicament for treating rheumatic lumbar disease and preparation method thereof | |
CN104815232A (en) | Traditional Chinese medicine preparation for treating primary pulmonary hypertension and preparation method thereof | |
CN104398873B (en) | It is a kind of for Chinese medicine preparation of external piles and preparation method thereof | |
CN115282229A (en) | Traditional Chinese medicine composition for treating coronary heart disease with syndrome of qi deficiency and blood stasis and preparation method thereof | |
CN104887950A (en) | Mastitis treatment traditional Chinese medicine compound | |
CN105477128A (en) | Traditional Chinese medicine composition with functions of dampness dissipating, leucorrhea arresting and endometritis prevention and control | |
CN104800610A (en) | Traditional Chinese medicine preparation for treating Parkinson's disease and preparation method thereof | |
CN104524535A (en) | Traditional Chinese medicine composition for treating chronic pulmonary heart disease and preparation method of traditional Chinese medicine composition | |
CN103330814A (en) | Traditional Chinese medicine composition for treating deficiency of kidney yang | |
CN110841007B (en) | Traditional Chinese medicine composition for treating cerebral apoplexy sequela and application thereof | |
CN102114140A (en) | Chinese medicine oral decoction for treating endometriosis | |
CN105663758A (en) | Folium artemisiae argyi containing traditional Chinese medicine composition for treating irregular menstruation and preparation method thereof | |
CN105169111A (en) | Traditional Chinese medicine composition for treating chronic urticaria and application of traditional Chinese medicine composition | |
CN105878732A (en) | A kind of traditional Chinese medicine for treating diabetes and preparation method thereof | |
CN105456933A (en) | Traditional Chinese medicine capable of activating blood to remove stasis and clearing and activating channels and collaterals and preparation method of traditional Chinese medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160113 |